Corcept Therapeutics (CORT) said Thursday the phase 2 trial of its experimental therapy, dazucorilant, did not meet its primary endpoint, sending shares down 1.4% in premarket activity.
Dazucorilant is intended to treat amyotrophic lateral sclerosis, a fatal motor neuron disease.
The company said the study showed that therapy did not meet its primary endpoint of improved outcome in the ALS functional rating scale-revised in patients who received dazucorilant compared to patients who received placebo.
However, no deaths occurred in the patient group receiving 300 mg of dazucorilant compared to five deaths in the placebo group, the company said, adding that an exploratory one-year analysis also demonstrated continued survival benefit, especially for those who stayed on 300 mg for over 24 weeks.
The long-term extension study is still ongoing, the company added.
Price: 68.99, Change: -0.99, Percent Change: -1.41
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.